Literature DB >> 16084496

Schisandrin B--a novel inhibitor of P-glycoprotein.

Pan Qiangrong1, Tao Wang, Qinghua Lu, Xun Hu.   

Abstract

P-glycoprotein-mediated drug efflux is one of the major causes of the cancer multidrug resistance (MDR). Inhibition of P-glycoprotein could reverse cancer MDR. Here, we show that schisandrin B, a naturally occurring compound from Schisandra chinensis (Turcz.) Baill, bears strong potency to inhibit P-glycoprotein. Schisandrin B reversed the drug resistance of four MDR cell lines characterized with overexpression of P-glycoprotein and fully restored the intracellular drug accumulation by interacting with P-glycoprotein. Schisandrin B has a core structure of dibenzocyclooctadiene, representing a novel P-glycoprotein inhibitor. To our best knowledge, the role of schisandrin B to inhibit P-glycoprotein has not been reported.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16084496     DOI: 10.1016/j.bbrc.2005.07.097

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers.

Authors:  Hua-Wen Xin; Xiao-Chun Wu; Qing Li; Ai-Rong Yu; Min Zhu; Yang Shen; Dan Su; Lei Xiong
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335

2.  Antitumor agents. 293. Nontoxic dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate (DDB) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs.

Authors:  Hsin-Yi Hung; Emika Ohkoshi; Masuo Goto; Kenneth F Bastow; Kyoko Nakagawa-Goto; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2012-05-21       Impact factor: 7.446

3.  Effects of Schisandra sphenanthera extract on the blood concentration of tacrolimus in renal transplant recipients.

Authors:  Hua-Wen Xin; Qing Li; Xiao-Chun Wu; Yan He; Ai-Rong Yu; Lei Xiong; Ying Xiong
Journal:  Eur J Clin Pharmacol       Date:  2011-06-09       Impact factor: 2.953

4.  Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo.

Authors:  Yang Xu; Zhen Liu; Jie Sun; Qiangrong Pan; Feifei Sun; Zhiyu Yan; Xun Hu
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

5.  Schisandra chinensis regulates drug metabolizing enzymes and drug transporters via activation of Nrf2-mediated signaling pathway.

Authors:  Jin-Lian He; Zhi-Wei Zhou; Juan-Juan Yin; Chang-Qiang He; Shu-Feng Zhou; Yang Yu
Journal:  Drug Des Devel Ther       Date:  2014-12-17       Impact factor: 4.162

6.  Schisandrin B reverses doxorubicin resistance through inhibiting P-glycoprotein and promoting proteasome-mediated degradation of survivin.

Authors:  Shengpeng Wang; Anqi Wang; Min Shao; Ligen Lin; Peng Li; Yitao Wang
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

7.  Effect of traditional Chinese medicine components on multidrug resistance in tumors mediated by P-glycoprotein.

Authors:  Xi Xia; Susan P C Cole; Tiange Cai; Yu Cai
Journal:  Oncol Lett       Date:  2017-04-03       Impact factor: 2.967

8.  Anticancer agent shikonin is an incompetent inducer of cancer drug resistance.

Authors:  Hao Wu; Jiansheng Xie; Qiangrong Pan; Beibei Wang; Danqing Hu; Xun Hu
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

9.  Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition.

Authors:  Zhen Liu; Biao Zhang; Kun Liu; Zonghui Ding; Xun Hu
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.752

10.  A Naturally-Derived Compound Schisandrin B Enhanced Light Sensation in the pde6c Zebrafish Model of Retinal Degeneration.

Authors:  Liyun Zhang; Lue Xiang; Yiwen Liu; Prahatha Venkatraman; Leelyn Chong; Jin Cho; Sylvia Bonilla; Zi-Bing Jin; Chi Pui Pang; Kam Ming Ko; Ping Ma; Mingzhi Zhang; Yuk Fai Leung
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.